

# Andrea Rubbert-Roth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6709996/publications.pdf>

Version: 2024-02-01

38  
papers

10,768  
citations

236925

25  
h-index

345221

36  
g-index

39  
all docs

39  
docs citations

39  
times ranked

9642  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
4	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2008, 371, 987-997.	13.7	1,269
5	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2513-2524.	13.7	316
6	Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. <i>Arthritis Research and Therapy</i> , 2009, 11, S1.	3.5	227
7	A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 69-74.	0.9	208
8	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.9	179
9	Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). <i>Rheumatology</i> , 2010, 49, 1683-1693.	1.9	170
10	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1081-1091.	0.9	152
11	Assessing the safety of biologic agents in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v38-v47.	1.9	121
12	Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 979-984.	0.9	119
13	A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.9	117
14	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
15	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	2.0	108
16	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
17	Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 68-74.	0.9	100
18	A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. <i>Rheumatology and Therapy</i> , 2018, 5, 21-42.	2.3	97

#	ARTICLE	IF	CITATIONS
19	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019, 18, 102398.	5.8	75
20	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1090-1097.	0.9	56
21	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 238-241.	0.9	54
22	Spectrum of Uveitis in A German Tertiary Center: Review of 474 Consecutive Patients. <i>Ocular Immunology and Inflammation</i> , 2015, 23, 346-352.	1.8	48
23	Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. <i>RMD Open</i> , 2016, 2, e000213.	3.8	47
24	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017, 56, kew370.	1.9	42
25	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018, 17, 24-28.	5.8	39
26	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	1.9	22
27	Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 4755-4764.	1.9	13
28	Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. <i>Rheumatology</i> , 2022, 62, 89-97.	1.9	13
29	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021, 8, 1661-1675.	2.3	10
30	Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 748-750.	1.3	9
31	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). <i>Rheumatology</i> , 2021, 60, 5318-5328.	1.9	8
32	Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 682-691.	1.9	7
33	Tocilizumab in Patients with Rheumatoid Arthritis and Rates of Malignancy: Results from Long-Term Extension Clinical Trials. <i>Rheumatology</i> , 2014, 53, i91-i92.	1.9	3
34	Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma. <i>Rheumatology</i> , 2022, , .	1.9	2
35	THU561...CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILL'S DISEASE TO ACHIEVE REDUCTION OF ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER). , 2019, , .		1
36	Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
37	Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 937-945.	0.8	1
38	Combination therapies in rheumatoid arthritisâ€”choose your partner carefully. <i>Lancet Rheumatology</i> , The, 2022, , .	3.9	0